Meropenem decreases serum level of valproic acid
dc.contributor.buuauthor | Nacarküçük, Ergün | |
dc.contributor.buuauthor | Sağlam, Halil | |
dc.contributor.buuauthor | Okan, Mehmet Sait | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0003-0710-5422 | tr_TR |
dc.contributor.researcherid | C-7392-2019 | tr_TR |
dc.contributor.scopusid | 6602924559 | tr_TR |
dc.contributor.scopusid | 35612700100 | tr_TR |
dc.contributor.scopusid | 6701707256 | tr_TR |
dc.date.accessioned | 2021-08-31T07:49:26Z | |
dc.date.available | 2021-08-31T07:49:26Z | |
dc.date.issued | 2004-09 | |
dc.description.abstract | Concomitant administration of meropenem has been reported to decrease serum level of valproic acid both in humans and in animals. This report describes three children who required simultaneous administration of valproic acid and meropenem. Meropenem rapidly decreased serum valproic acid concentration to sub-therapeutic levels in all three children, and serum valproic acid levels were returned to therapeutic levels in a short time after discontinuing simultaneous meropenem therapy. Valproic acid was not changed to another antiepileptic agent, because no seizure activity was observed. To our knowledge, this is the first case report on the simultaneous administration of meropenem and valproic acid in childhood. In conclusion, it is clear that concomitant meropenem administration decreases serum valproic acid concentration, and we believe that there may be no need to change the antiepileptic drug during this period, provided that the patient has no seizure. More detailed studies are required. | en_US |
dc.identifier.citation | Nacarküçük, E. vd. (2004). “Meropenem decreases serum level of valproic acid”. Pediatric Neurology, 31(3), 232-234. | en_US |
dc.identifier.endpage | 234 | tr_TR |
dc.identifier.issn | 0887-8994 | |
dc.identifier.issue | 3 | tr_TR |
dc.identifier.pubmed | 15351028 | tr_TR |
dc.identifier.scopus | 2-s2.0-4544265039 | tr_TR |
dc.identifier.startpage | 232 | tr_TR |
dc.identifier.uri | https://doi.org/10.1016/j.pediatrneurol.2004.03.014 | |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S088789940400219 | |
dc.identifier.uri | http://hdl.handle.net/11452/21569 | |
dc.identifier.volume | 31 | tr_TR |
dc.identifier.wos | 000224077600016 | tr_TR |
dc.indexed.pubmed | Pubmed | tr_TR |
dc.indexed.scopus | Scopus | tr_TR |
dc.indexed.wos | SCIE | tr_TR |
dc.language.iso | en | en_US |
dc.publisher | Elsevier Science | en_US |
dc.relation.journal | Pediatric Neurology | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Neurosciences & neurology | en_US |
dc.subject | Pediatrics | en_US |
dc.subject | Safety profile | en_US |
dc.subject | Carbapenem | en_US |
dc.subject | Pharmacokinetics | en_US |
dc.subject | Panipenem | en_US |
dc.subject | Rabbits | en_US |
dc.subject | Plasma | en_US |
dc.subject | Rats | en_US |
dc.subject.emtree | Ceftazidime | en_US |
dc.subject.emtree | Meropenem | en_US |
dc.subject.emtree | Tobramycin | en_US |
dc.subject.emtree | Valproic acid | en_US |
dc.subject.emtree | Vancomycin | en_US |
dc.subject.emtree | Adolescent | en_US |
dc.subject.emtree | Case report | en_US |
dc.subject.emtree | Cerebral palsy | en_US |
dc.subject.emtree | Child | en_US |
dc.subject.emtree | Clinical feature | en_US |
dc.subject.emtree | Dose calculation | en_US |
dc.subject.emtree | Drug blood level | en_US |
dc.subject.emtree | Drug brain level | en_US |
dc.subject.emtree | Drug glucuronidation | en_US |
dc.subject.emtree | Drug withdrawal | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Hospital admission | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Patient monitoring | en_US |
dc.subject.emtree | Pneumonia | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Seizure | en_US |
dc.subject.emtree | Seizure susceptibility | en_US |
dc.subject.mesh | Adolescent | en_US |
dc.subject.mesh | Drug interactions | en_US |
dc.subject.mesh | Drug therapy, combination | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Infant | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Thienamycins | en_US |
dc.subject.mesh | Valproic acid | en_US |
dc.subject.scopus | Carbapenems; Valproic Acid; Acylamino Acid Releasing Enzyme | en_US |
dc.subject.wos | Clinical neurology | en_US |
dc.subject.wos | Pediatrics | en_US |
dc.title | Meropenem decreases serum level of valproic acid | en_US |
dc.type | Article | |
dc.wos.quartile | Q2 (Pediatrics) | en_US |
dc.wos.quartile | Q3 (Clinical neurology) | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: